Impact of prior treatment history on efficacy of Risankizumab compared with placebo in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials

被引：0
|
作者：
Strober, B. [1 ,2 ]
Lambert, J. [3 ]
Gu, Y. [4 ]
Zhan, T. [4 ]
Thompson, E. Z. [5 ]
Valdecantos, W. C. [4 ]
Menter, A. [6 ]
机构：
[1] Univ Connecticut, Ctr Hlth, Farmington, CT USA
[2] Prob Med Res, Farmington, CT USA
[3] Ghent Univ Hosp, Dept Dermatol, Ghent, Belgium
[4] AbbVie Inc, N Chicago, IL USA
[5] AbbVie Inc, Redwood City, CA USA
[6] Baylor Univ, Med Ctr, Div Dermatol, Dallas, TX USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P100
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [41] Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Rosmarin, David
    Lebwohl, Mark
    Peterson, Luke
    Madden, Cynthia
    de Cuyper, Dirk
    Davies, Owen
    Thaci, Diamant
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (04) : 477 - 485
  • [42] Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis
    Ambikaibalan, Danni
    Quaade, Anna Sophie
    Halling, Anne-Sofie
    Thyssen, Jacob P.
    Egeberg, Alexander
    DERMATOLOGY, 2021, 237 (02) : 158 - 165
  • [43] Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies
    Strober, B.
    Menter, A.
    Leonardi, C.
    Gordon, K.
    Lambert, J.
    Puig, L.
    Photowala, H.
    Longcore, M.
    Zhan, T.
    Foley, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (12) : 2830 - 2838
  • [44] Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial
    Blauvelt, Andrew
    Leonardi, Craig L.
    Gooderham, Melinda
    Papp, Kim A.
    Philipp, Sandra
    Wu, Jashin J.
    Igarashi, Atsuyuki
    Flack, Mary
    Geng, Ziqian
    Wu, Tianshuang
    Camez, Anne
    Williams, David
    Langley, Richard G.
    JAMA DERMATOLOGY, 2020, 156 (06) : 649 - 658
  • [45] Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
    Crowley, Jeffrey J.
    Langley, Richard G.
    Gordon, Kenneth B.
    Pinter, Andreas
    Ferris, Laura K.
    Rubant, Simone
    Photowala, Huzefa
    Xue, Zhenyi
    Wu, Tianshuang
    Zhan, Tianyu
    Beeck, Stefan
    Shah, Megha
    Warren, Richard B.
    DERMATOLOGY AND THERAPY, 2022, 12 (02) : 561 - 575
  • [46] Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
    Jeffrey J. Crowley
    Richard G. Langley
    Kenneth B. Gordon
    Andreas Pinter
    Laura K. Ferris
    Simone Rubant
    Huzefa Photowala
    Zhenyi Xue
    Tianshuang Wu
    Tianyu Zhan
    Stefan Beeck
    Megha Shah
    Richard B. Warren
    Dermatology and Therapy, 2022, 12 : 561 - 575
  • [47] Efficacy and safety of guselkumab for the treatment of patients with moderate-to-severe plaque psoriasis: A meta-analysis of randomized clinical trials
    Tao, Xing-Bao
    Huang, Yin-Qiu
    Zhou, Yi-Hong
    Zhang, Lv-Lang
    Chen, Yao-Kai
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (02) : 433 - 440
  • [48] Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: An overview of 3 randomized controlled trials
    Blauvelt, Andrew
    Reich, Kristian
    Drew, Janice
    Peterson, Luke
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB239 - AB239
  • [49] Secukinumab compared to placebo for effect on subcutaneous adipose tissue and skin inflammation in patients with moderate-to-severe plaque psoriasis
    Krueger, James G.
    Siu, Kimberly
    Kianifard, Farid
    Steadman, Jennifer
    Nyirady, Judit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB227 - AB227
  • [50] Ixekizumab impact on health-related quality of life compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis
    Reich, Kristian
    Toth, Darryl
    Nikai, Enkeleida
    Zhu, Baojin
    Carlier, Hilde
    Feldman, Steven
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S35 - S35
12345